Next-generation sequencing

Capture the complexity of myeloid neoplasms with targeted NGS

Unraveling the mutational landscape of myeloid neoplasms

Myeloid neoplasms are a group of diseases characterized by a wide range of mutations across multiple genes, including oncogenes and tumor suppressor genes. These genes include CALR and CEBPA for acute myeloid leukemia (AML) and TP53 or RB1 for chronic myeloid leukemia (CML). Targeted NGS has the potential to reveal the mutational landscape of myeloid neoplasms comprehensively. But everything hinges on choosing the right panel. Low allele frequency of variants, high GC content, low enrichment of target DNA and ultra-long workflows can delay insights. Skip the drama and detect low-frequency variants with high confidence. Our QIAseq Targeted DNA Pro Panel for myeloid neoplasms has been developed with your challenges in mind.

Top 5 reasons why you should upgrade to the QIAseq Targeted DNA Pro Human Myeloid Neoplasms Focus Panel:

“QIAseq Targeted DNA Pro 文库制备的手动操作时间减少到 6 小时左右，这意味着我们可以在一天内完成文库制备。这对于周转时间很短的癌症研究实验室来说非常有吸引力。”

Barnaby Clark 博士，国王学院医院 NHS Foundation Trust 精准医学实验室负责人

Don’t dread data analysis and interpretation – we’ve got you covered

Analyze with precision. Interpret with confidence. The QIAseq workflow lets you seamlessly go from sequencing library to secondary analysis and interpretation. This means you can reliably detect difficult and rare variants below 1% VAF.

Secondary data analysis: QIAGEN CLC Genomics Workbench

The user-friendly QIAGEN CLC Genomics Workbench provides comprehensive analysis of your NGS data and offers advanced NGS workflows for targeted panel support and variant calling. Detect difficult variants, such as SRSF2, CEBPA and CALR mutations, and call variants below 1% VAF with the combined QIAseq Targeted DNA Pro Human Myeloid Neoplasms Panel and CLC Genomics Workbench workflow.

Learn more

Interpret your results with QIAGEN Clinical Insight (QCI) Interpret for Oncology

This platform, powered by augmented molecular intelligence, enables rapid, evidence-based comprehensive genomic profiling at scale. Connected to the QIAGEN Knowledge Base, QCI Interpret for Oncology dynamically computes pathogenicity and actionability based on the AMP/ASCO/CAP or ACMG/AMP guidelines for every variant in over 31,000 cancer types with complete transparency. You can access over 410,000 preformulated, oncologist-reviewed variant impact summaries to simplify and accelerate interpretation.